We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Autolus Therapeutics PLC | NASDAQ:AUTL | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.80 | 3.75 | 4.21 | 0 | 09:00:00 |
From Oct 2023 to Apr 2024
By Josh Beckerman
Cabaletta Bio shares were down 32% to $12.72 after the U.S. Food and Drug Administration said it is looking into reports of T-cell malignancies in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
Cantor Fitzgerald analyst Josh Schimmer also mentioned Gracell Biotechnologies and Autolus Therapeutics as stocks that were "obviously" down in connection with the FDA's announcement. Gracell was recently down 17% to $4.46 while Autolus declined 11% to $4.50. Schimmer said the FDA investigation is "Likely a Storm in A Tea Cup."
The FDA lists several approved products in the category, such as Yescarta from Gilead Sciences. It said "the overall benefits of these products continue to outweigh their potential risks for their approved uses."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 28, 2023 14:44 ET (19:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Autolus Therapeutics Chart |
1 Month Autolus Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
